Edwards Lifesciences – Mitral and Tricuspid Therapies at PCR London Valves 2021

Published: 27 November 2021

  • Views:

    Views Icon 21078
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Filmed around PCR London Valves 2021, this programme brings together three opinion leaders to discuss the latest in mitral and tricuspid therapies in the Edwards’ portfolio. Chair Prof Philipp Lurz (Heart Center Leipzig of University Leipzig, DE) is joined by Dr Sam Dawkins (John Radcliffe Hospital, Oxford, UK) and Prof Nicole Karam (Georges Pompidou European Hospital University of Paris, FR) to summarise the challenges facing MR and TR, and review latest data supporting strategies to achieve optimal patient outcomes.

This programme is supported by

More from this programme

Part 1

Part 1 – Edwards Lifesciences Mitral and Tricuspid Therapies at PCR London Valves 2021 – Introduction

In this first part, Prof Lurz provides an introduction to Edwards’ transcatheter portfolio, and summarises the pivotal studies underpinning the emergence of a compelling body of clinical evidence supporting both mitral (SAPIEN M3 Valve, EVOQUE Eos valve, PASCAL platform, Cardioband mitral system) and tricuspid (EVOQUE replacement system, Cardioband tricuspid system, and PASCAL platform) portfolios.

Part 2

Part 2 – Seeing is Believing: Predictable and Durable Treatment of MR Across Etiologies With the PASCAL Platform

Dr Dawkins guides us through PASCAL platform experience and outcomes from over 3,800 MR patients, the operator learning curve, and MR reduction rates in real-world settings. He continues to review the finding of MiCLASP at 30-day follow-up, and CLASP study at 2-year follow-up.

Part 3

Part 3 – Edwards' Transcatheter Trilogy: An Exclusive Portfolio of Three Options to Treat TR

Prof Karam discusses the challenges and needs for the effective treatment of tricuspid valve disease, and draws upon multi-centre experience to provide insight into the effective use of the PASCAL platform. In addition, Prof Karam summarises significant and sustained annular reduction and consequently TR reduction with Cardioband Tricuspid System, data indicating significant TR reduction in laboratory assessments with the EVOQUE2* Valve.

Faculty Biographies

Nicole Karam

Nicole Karam

Prof Nicole Karam is an associate professor in the Department of Cardiology at the European Hospital Georges Pompidou. She specializes in interventional cardiology and performs both coronary and valvular percutaneous surgeries, as well as research in Cardiovascular Epidemiology at the French National Institute of Health and Medical Research.

After starting her medical studies at Saint-Joseph University in Beirut, she moved to Paris in 2010 and specialized in Interventional Cardiology. Subsequently, she trained in a highly specialized center for valvular heart disease in Munich, Germany, where she learned new techniques in percutaneous valvular interventions that she later brought back to Georges Pompidou Hospital.

Prof Karam is an active member and a fellow of the European Society of Cardiology, and a member of the steering committee of the Women’s European Association of Percutaneous Cardiovascular Interventions. 

View full profile
Philipp Lurz

Philipp Lurz

University Medical Center Mainz, Mainz, Germany

Prof Philipp Lurz is Director of the Department of Cardiology Universitätsmedizin Mainz, Germany. Prior to this, he served as Deputy Head of the Department at Heart Center Leipzig, Germany. Previously, Prof Lurz was a Clinical Research Fellow at Great Ormond Street Hospital for Children NHS Foundation Trust. He completed his education at the University of Leipzig, and is a member of the German Society of Cardiology. Philipp is widely published in leading international peer-reviewed journals.

View full profile